The Q·Score Snapshot
LLY scores 8 out of 10, carrying a "Bullish" Q·Score label. The Q·Score aggregates fundamental, growth, and analyst sentiment signals into a single composite — a score of 8 reflects that the overwhelming majority of those inputs are pointing in the same direction. The score describes what the data shows collectively; it does not signal what any individual investor should do with it.
Business at a Glance
Eli Lilly is a global pharmaceutical company headquartered in Indianapolis, operating squarely within the Healthcare sector. Its current data profile is being driven in large part by the explosive commercial uptake of its GLP-1 class drugs — tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity — which have reshaped the company's revenue trajectory over the past two years. The broader weight-loss and metabolic disease market has become one of the most closely watched growth vectors in all of large-cap healthcare, and Lilly sits at its centre.
The Numbers That Stand Out
Revenue growth of 55.5% year-over-year is a striking figure for a company with a market capitalisation already above $1 trillion — at that scale, sustaining that pace of top-line expansion is operationally rare. Earnings growth of 169.9% indicates that profitability is scaling faster than revenue, a sign that operating leverage is kicking in as manufacturing capacity catches up with demand. The 35% net profit margin — net profit as a share of total revenue — places Lilly among the most profitable large pharmaceutical companies globally. A return on equity of 107.5% (net income divided by shareholders' equity) reflects how efficiently the business is converting the capital shareholders have invested into profit. Finally, the 100% EPS beat rate — meaning Lilly has exceeded analyst earnings-per-share estimates in every measured reporting period in the dataset — points to a pattern of management either under-promising or consistently outperforming expectations.
What Analysts Think
Of the 29 analysts currently covering LLY, 77% carry a positive rating on the stock, indicating a clear lean toward optimism across the covering community. The consensus price target implies approximately 7.8% upside from the current price of $1,126.80, suggesting analysts as a group see measured room above current levels rather than a dramatic gap. It is worth noting that with a stock that has moved as sharply as LLY has in recent years, the gap between price and target can compress quickly — the 7.8% figure reflects where consensus targets stand as of this publication date.
The Bigger Picture
Within the Healthcare sector, Lilly's current data profile marks it as an outlier rather than a representative name — most large-cap pharmaceutical peers are not posting revenue growth in the mid-50s percentage range or earnings growth approaching 170%. The company's forward P/E — the current stock price divided by the next twelve months' expected earnings per share — stands at approximately 25.3x, which is notably lower than the multiples often associated with high-growth technology companies, reflecting the market's attempt to price in both the growth trajectory and the inherent risks of pharmaceutical revenue concentration. Whether the GLP-1 wave sustains its momentum, faces new competition, or encounters supply constraints are the structural questions the numbers alone cannot answer — but as a data snapshot, the figures Lilly is currently producing are among the most discussed in the sector.